A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients

Oncology Reports

Volumn 24, Issue 3, 2010, Pages 795-801

  Yanagimoto, Hiroaki ^a   Shiomi, Hisanori ^b   Satoi, Sohei ^a   Mine, Takashi ^c   Toyokawa, Hideyoshi ^a   Yamamoto, Tomohisa ^a   Tani, Tohru ^b   Yamada, Akira ^c   Kwon, A Hon ^a   Komatsu, Nobukazu ^c   Itoh, Kyogo ^c   Noguchi, Masanori ^c  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Gemcitabine; Immunotherapy; Pancreatic cancer; Peptide vaccination

Indexed keywords

GEMCITABINE; HLA A2 ANTIGEN; HLA A24 ANTIGEN; PEPTIDE VACCINE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNIZATION; CANCER PATIENT; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; HYPERBILIRUBINEMIA; IMMUNE RESPONSE; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; PLASMA; PRIORITY JOURNAL; SIDE EFFECT; SKIN MANIFESTATION; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CANCER VACCINES; DEOXYCYTIDINE; FEMALE; HLA ANTIGENS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; VACCINES, SUBUNIT;

EID: 77956310379     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000923     Document Type: Article

References (17)

1. Li D, Xie K, Wolff R and Abbruzzes JL: Pancreatic cancer. Lancet 363: 1049-1059, 2004.
2. Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997. (Pubitemid 27251144)
3. Novellino L, Castelli C and Parmiani G: A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immuno Immunother 54: 187-207, 2005.
4. Rosenberg SA: A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10: 281-287, 1999.
5. Rosenberg SA, Yang JC and Rastifo NP: Cancer immunotherapy: moving beyond current vaccines. Nat Med 10: 909-915, 2004.
6. Noguchi M, Kobayashi K, Suetsugu N, et al: Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate 57: 80-92, 2003.
7. Mine T, Sato Y, Noguchi M, et al: Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing peptide-specific cellular responses. Clin Cancer Res 10: 929-937, 2004.
8. + HRPC patients. Prostate 63: 1-12, 2005.
9. Sato Y, Fujiwara T, Mine T, et al: Immunological evaluation of personalized peptide vaccination in combination with a 5- fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients. Cancer Sci 98: 1113-1119, 2007.
10. Yanagimoto H, Mine T, Yamamoto K, et al: Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer. Cancer Sci 98: 605-611, 2007. (Pubitemid 46562753)
11. Hida N, Maeda Y, Katagiri K, Takasu H, Harada M and Itoh K: A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in circulation. Cancer Immunol Immunotherapy 51: 219-228, 2002.
12. Komatsu N, Shichijo S, Nakagawa M and Itoh K: New multi-plexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization. Scand J Cin Lab Invest 64: 1-11, 2004.
13. Li J and Saif MW: Any progress in the management of advanced pancreatic cancer? J Pancreas 10: 361-365, 2009.
14. Heinemann V, Quietzsch D, Gieseler F, et al: Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24: 3946-3952, 2006.
15. Louvet C, Labianca R, Hammel P, et al: Gemcitabine in combination with oxaliplatin compared with gemcitabine in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23: 3509-3516, 2005.
16. Bernhardt SL, Gjertsen MK, Trachsel S, et al: Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. Br J Cancer 95: 1474-1482, 2006. (Pubitemid 44863349)
17. Buanes T, Maurel J, Liauw W, Hebbar M and Nemunaitis J: A randomized phase III study of gemcitabine (G) versus GV1001 in sequential combination with G in patients with unresectable and metastatic pancreatic cancer (PC). J Clin Oncol 27 (Suppl. 15): abs. 4601, 2009.